These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 35651980)
1. BRAF Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980 [No Abstract] [Full Text] [Related]
2. MicroRNA-150-5p affects cell proliferation, apoptosis, and EMT by regulation of the BRAF Yan R; Yang T; Zhai H; Zhou Z; Gao L; Li Y J Cell Biochem; 2018 Nov; 119(11):8763-8772. PubMed ID: 30126001 [TBL] [Abstract][Full Text] [Related]
3. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953 [TBL] [Abstract][Full Text] [Related]
4. Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers. Han PA; Kim HS; Cho S; Fazeli R; Najafian A; Khawaja H; McAlexander M; Dy B; Sorensen M; Aronova A; Sebo TJ; Giordano TJ; Fahey TJ; Thompson GB; Gauger PG; Somervell H; Bishop JA; Eshleman JR; Schneider EB; Witwer KW; Umbricht CB; Zeiger MA Thyroid; 2016 Apr; 26(4):532-42. PubMed ID: 26950846 [TBL] [Abstract][Full Text] [Related]
5. BRAF Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810 [TBL] [Abstract][Full Text] [Related]
7. Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness. Zhang T; Shen X; Liu R; Zhu G; Bishop J; Xing M Oncotarget; 2017 Jan; 8(1):900-914. PubMed ID: 27863429 [TBL] [Abstract][Full Text] [Related]
8. Down-regulation of 14q32-encoded miRNAs and tumor suppressor role for miR-654-3p in papillary thyroid cancer. Geraldo MV; Nakaya HI; Kimura ET Oncotarget; 2017 Feb; 8(6):9597-9607. PubMed ID: 28030816 [TBL] [Abstract][Full Text] [Related]
9. Targeting miR-31 represses tumourigenesis and dedifferentiation of BRAF Zhang P; Guan L; Sun W; Zhang Y; Du Y; Yuan S; Cao X; Yu Z; Jia Q; Zheng X; Meng Z; Li X; Zhao L Clin Transl Med; 2024 May; 14(5):e1694. PubMed ID: 38797942 [TBL] [Abstract][Full Text] [Related]
10. Up-regulation of urinary-type plasminogen activator correlates with high-risk papillary thyroid carcinoma with BRAF(V600E) mutation and its possible molecular mechanism. Wakasa T; Li Y; Bai Y; Liu Z; Ozaki T; Mori I; Miyauchi A; Kakudo K; Nakamura M Pathol Res Pract; 2014 Nov; 210(11):733-8. PubMed ID: 25085839 [TBL] [Abstract][Full Text] [Related]
11. BRAF-activated WT1 contributes to cancer growth and regulates autophagy and apoptosis in papillary thyroid carcinoma. Chen X; Lin S; Lin Y; Wu S; Zhuo M; Zhang A; Zheng J; You Z J Transl Med; 2022 Feb; 20(1):79. PubMed ID: 35123502 [TBL] [Abstract][Full Text] [Related]
12. MicroRNA-99a-3p/GRP94 axis affects metastatic progression of human papillary thyroid carcinoma by regulating ITGA2 expression and localization. Gao Y; Pan Y; Wang T; Yao Y; Yuan W; Zhu X; Wang K Acta Biochim Biophys Sin (Shanghai); 2021 Dec; 53(12):1650-1661. PubMed ID: 34687203 [TBL] [Abstract][Full Text] [Related]
13. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337 [TBL] [Abstract][Full Text] [Related]
14. The BRAF Ma CX; Ma XN; Liu JJ; Guan CH; Li YD; Zhao N; Mauricio D; Fu SB Mol Cell Endocrinol; 2024 Feb; 581():112113. PubMed ID: 37989409 [TBL] [Abstract][Full Text] [Related]
15. Risk and Prognostic Factors for BRAF Wei X; Wang X; Xiong J; Li C; Liao Y; Zhu Y; Mao J Biomed Res Int; 2022; 2022():9959649. PubMed ID: 35647194 [TBL] [Abstract][Full Text] [Related]
16. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600E mutation and microRNAs are helpful in distinguishing papillary thyroid malignant lesions: Tissues and fine needle aspiration cytology cases. Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Nozhat Z; Fanaei SA; Hedayati M; Azizi F Life Sci; 2019 Apr; 223():166-173. PubMed ID: 30890403 [TBL] [Abstract][Full Text] [Related]
20. MicroRNA Deregulation in Papillary Thyroid Cancer and its Relationship With BRAF V600E Mutation. Celakovsky P; Kovarikova H; Chrobok V; Mejzlik J; Laco J; Vosmikova H; Chmelarova M; Ryska A In Vivo; 2021; 35(1):319-323. PubMed ID: 33402480 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]